tiprankstipranks
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
HKEX:2315
Hong Kong Market
2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
RESEARCH TOOLSreports
Holding HK:2315?
Track your performance easily

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

2315 Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Biocytogen
Pharmaceuticals (Beijing) Co. Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2315 Stock 12 Month Forecast

There Are No Analyst Ratings for HK:2315 In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

2315 Financial Forecast

2315 Earnings Forecast

Next quarter’s earnings estimate for 2315 is HK$0.01 with a range of HK$0.01 to HK$0.01. The previous quarter’s EPS was -HK$0.14. 2315 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.47% of the time in the same period. In the last calendar year 2315 has Underperformed its overall industry.
Next quarter’s earnings estimate for 2315 is HK$0.01 with a range of HK$0.01 to HK$0.01. The previous quarter’s EPS was -HK$0.14. 2315 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.47% of the time in the same period. In the last calendar year 2315 has Underperformed its overall industry.

2315 Sales Forecast

Next quarter’s sales forecast for 2315 is HK$576.71M with a range of HK$576.71M to HK$576.71M. The previous quarter’s sales results were HK$444.83M. 2315 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 51.03% of the time in the same period. In the last calendar year 2315 has Outperformed its overall industry.
Next quarter’s sales forecast for 2315 is HK$576.71M with a range of HK$576.71M to HK$576.71M. The previous quarter’s sales results were HK$444.83M. 2315 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 51.03% of the time in the same period. In the last calendar year 2315 has Outperformed its overall industry.

2315 Analyst Recommendation Trends

Rating
Aug 23
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
total
1
In the current month, 2315 has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2315 average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

2315 Stock Forecast FAQ

What is HK:2315’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:2315’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:2315, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H a Buy, Sell or Hold?
      Currently, no data Available
      What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s share price target?
      Currently, no data Available
      What do analysts say about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
      To buy shares of HK:2315, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis